VRSA stands for vancomycin-resistant Staphylococcus aureus, a rare and serious form of staph bacteria that no longer responds to vancomycin, one of the most powerful antibiotics used to treat severe staph infections. Only 16 confirmed cases have been reported in the United States since the first was identified in 2002, making it one of the rarest antibiotic-resistant infections tracked by the CDC.
How VRSA Differs From MRSA
Most people searching for VRSA already know about MRSA, which is staph bacteria resistant to a common class of antibiotics. VRSA takes resistance a step further. Vancomycin has long been the go-to drug when MRSA infections don’t respond to other treatments. When staph bacteria develop resistance to vancomycin as well, treatment options narrow considerably.
The distinction comes down to how much vancomycin it takes to kill the bacteria in a lab setting. Fully resistant VRSA requires a concentration of 16 micrograms per milliliter or higher to be inhibited. There’s also an intermediate category called VISA, where the bacteria show reduced susceptibility (requiring 4 to 8 micrograms per milliliter) but aren’t fully resistant. VRSA is the more dangerous of the two because standard vancomycin dosing simply won’t work.
How Bacteria Become Vancomycin-Resistant
Vancomycin works by binding to specific building blocks on the bacterial cell wall, preventing the wall from being assembled. Without a functional cell wall, the bacterium dies. VRSA bacteria carry a gene cluster called vanA that changes those building blocks just enough that vancomycin can no longer latch on.
The concerning part is where that gene comes from. Staph bacteria don’t develop vanA on their own. They acquire it from a different species entirely: vancomycin-resistant enterococci (VRE), a gut bacteria that already carries the resistance gene. When a patient is colonized or infected with both staph and VRE at the same time, the resistance gene can jump between species. This transfer happens through mobile pieces of DNA, including a transposon called Tn1546, which can shuttle between bacteria on shared genetic packages called plasmids. In some cases, the entire resistance-carrying plasmid integrates directly into the staph chromosome at specific docking sites, making the resistance permanent.
This gene-swapping ability is what makes public health officials so vigilant. Every co-infection with MRSA and VRE is a potential opportunity for VRSA to emerge.
Who Is Most at Risk
The profile of VRSA patients in the U.S. is remarkably consistent. Nearly all confirmed cases have involved people with chronic wounds, particularly on the lower legs and feet, combined with underlying conditions like diabetes and kidney disease requiring dialysis. Of the 16 U.S. cases, 8 were identified in southeastern Michigan, and most involved foot or plantar ulcers.
The common risk factors include:
- Chronic wounds lasting two or more years, especially on the feet and lower legs
- Diabetes, which appeared in the vast majority of confirmed cases
- Kidney disease requiring dialysis, which involves repeated healthcare contact and catheter use
- Previous MRSA infections, meaning the patient was already carrying resistant staph
- Recent or prolonged vancomycin use, which creates selective pressure favoring resistant bacteria
- Indwelling medical devices like catheters, which provide bacteria a surface to colonize
Having chronic wounds for more than two years was the strongest common thread across cases. These wounds create a long-term environment where staph and enterococci can coexist, giving the bacteria repeated opportunities to exchange resistance genes.
Where VRSA Has Been Found
In the United States, VRSA remains extremely rare. The 16 confirmed cases span from 2002 to 2021, with most concentrated in Michigan (9 cases) and Delaware (4 cases), plus individual cases in Pennsylvania, New York, and North Carolina. The patients ranged in age from 40 to 88, and their infections typically involved foot wounds, plantar ulcers, or surgical sites.
Globally, the picture looks different. A large systematic review found VRSA prevalence of about 5% among tested staph isolates in Asia, 16% in Africa, 4% in South America, and 1% in Europe. The highest reported rates were in Nigeria (29% of tested isolates) and Saudi Arabia (18%). The most research reports came from Iran and India. No cases have been reported from Oceania. These numbers suggest VRSA is far more common in parts of Africa and Asia than in Western countries, though differences in testing standards and reporting make direct comparisons difficult.
What VRSA Infections Look Like
VRSA doesn’t cause a unique set of symptoms that distinguish it from other staph infections. It causes the same types of infections as regular staph or MRSA: wound infections, soft tissue infections, bone infections (osteomyelitis), and occasionally deeper infections at surgical sites. Among the U.S. cases, the most common presentations were infected chronic foot wounds, osteomyelitis, and soft tissue infections. One case involved necrotizing fasciitis, a rapidly spreading soft tissue infection.
What sets VRSA apart isn’t how it looks but how it responds to treatment. A wound infection that fails to improve despite vancomycin therapy may prompt the lab to test specifically for elevated resistance levels. This is how most cases have been caught: a clinical failure leads to closer laboratory scrutiny.
How VRSA Is Detected
Identifying VRSA requires specific laboratory testing. Standard automated systems used in many hospital labs can miss it. The CDC recommends broth microdilution, where bacteria are exposed to precise concentrations of vancomycin in liquid growth media, as the gold standard. Labs also use vancomycin agar screening plates. Both methods follow guidelines from the Clinical and Laboratory Standards Institute and require a full 24-hour incubation period at body temperature, with careful examination for any signs of bacterial growth.
When a potential VRSA isolate is identified, the lab is expected to confirm the result and notify public health authorities. The CDC treats every confirmed case as a public health event requiring investigation.
Treatment and Hospital Response
Because vancomycin is off the table, treatment relies on alternative antibiotics that VRSA strains remain susceptible to. The specific drug depends on the individual bacteria’s sensitivity profile, which is determined through lab testing. Most confirmed U.S. cases have been treatable with other available antibiotics, though the options are more limited than for ordinary staph infections.
The hospital response to a confirmed VRSA case is intense. The CDC’s containment protocol calls for isolating the patient in a private room, assigning dedicated staff who care only for that patient, and requiring gowns and gloves for anyone entering the room. Non-disposable equipment like blood pressure cuffs must be dedicated to the patient and not shared. The patient’s medical chart is flagged, and health authorities must be consulted before any transfer or discharge. These precautions stay in place until the patient tests negative on three separate occasions over three weeks, or until the infection has fully healed.
Every healthcare facility the patient visited during the period when transmission could have occurred is notified so that additional screening and precautions can be put in place. The goal is to prevent VRSA from establishing itself and spreading the way MRSA did decades earlier.
Why VRSA Hasn’t Spread Like MRSA
Given how alarming vancomycin resistance sounds, the natural question is why VRSA hasn’t become widespread. Part of the answer is biological. Acquiring the vanA gene requires a specific set of circumstances: the right staph strain, co-colonization with VRE, and successful gene transfer. Even when transfer occurs, the resistance genes can impose a fitness cost on the bacteria, potentially making them less competitive in the absence of vancomycin pressure.
The other part is the aggressive public health response. Every confirmed case triggers a full investigation with strict containment measures, contact tracing, and environmental decontamination. This level of response has, so far, prevented sustained transmission. But the rising prevalence of VRSA in parts of Africa and Asia, where surveillance and containment resources may be more limited, suggests this success isn’t guaranteed to hold everywhere indefinitely.